Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: water for injections; sodium acetate - tramal solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tramadol hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium acetate; water for injections - tramal solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besilate, quantity: 6.7 mg/ml (equivalent: cisatracurium, qty 5 mg/ml) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - nimbex injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besilate, quantity: 2.68 mg/ml (equivalent: cisatracurium, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - other conditions: protect from light. nimbex injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besilate, quantity: 2.68 mg/ml (equivalent: cisatracurium, qty 2 mg/ml) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - nimbex injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: sodium chloride; sodium citrate; citric acid; water for injections - wockhadrine injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: sodium chloride; sodium citrate; citric acid; water for injections - ephedrine interpharma injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - papaverine hydrochloride, quantity: 12 mg/ml - injection, solution - excipient ingredients: water for injections - papaverine hydrochloride injection is indicated for the treatment of erectile dysfunction.